News, features, and commentary about cancer-related issues ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...

Former first lady Jill Biden has issued a rare health update on Joe Biden's battle with prostate cancer, saying that the former president is "doing well." ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging ...

In this retrospective study, researchers sought to determine the efficacy, safety, and effectiveness of a reduced ARSI dose compared to a full dose in non-metastatic castration-resistant prostate ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...